Reference: https://pubmed.ncbi.nlm.nih.gov/39956927/
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, encompassing conditions such as arrhythmias, coronary atherosclerotic heart disease, and hypertension. Resveratrol (RSV), a natural nonflavonoid phenolic compound, has garnered attention for its diverse biological activities, including antioxidant, anti-inflammatory, anticancer, and notably, cardiovascular protective effects.
Despite its therapeutic potential, RSV's clinical application is hindered by its susceptibility to oxidation and rapid metabolism, necessitating structural optimization to enhance its stability and efficacy.
In their 2025 review published in Archiv der Pharmazie, Yaling Peng and colleagues delve into the advancements concerning RSV and its derivatives in the context of CVDs. The authors systematically explore the synthesis of RSV derivatives, their structure-activity relationships, and the underlying mechanisms by which they exert cardiovascular protection. This comprehensive analysis aims to bridge the gap between RSV's promising pharmacological profile and its practical therapeutic application.
The review highlights various strategies employed to enhance RSV's bioavailability and stability. Chemical modifications, such as the introduction of methoxy groups or glycosylation, have been investigated to improve RSV's resistance to metabolic degradation. These structural alterations not only prolong the compound's half-life but also potentially augment its therapeutic potency against cardiovascular pathologies.
Furthermore, the authors discuss the mechanistic pathways through which RSV and its derivatives confer cardiovascular benefits. Key mechanisms include the attenuation of oxidative stress, modulation of inflammatory responses, and improvement of endothelial function. By scavenging reactive oxygen species and inhibiting pro-inflammatory mediators, RSV helps in preserving vascular integrity and preventing atherosclerotic developments.
The review also addresses the challenges and future directions in translating RSV research into clinical practice. Emphasis is placed on the need for extensive in vivo studies and clinical trials to validate the efficacy and safety of optimized RSV derivatives. Additionally, exploring novel delivery systems, such as nanoparticle-based carriers, could further enhance the therapeutic potential of RSV in managing CVDs.
In summary, while RSV presents a promising natural compound for cardiovascular therapy, its clinical utility is limited by inherent instability and rapid metabolism. Advancements in chemical modification and a deeper understanding of its mechanistic actions offer a pathway to harnessing RSV's full therapeutic potential.
Ongoing research and development are crucial to overcoming existing limitations and facilitating the integration of RSV-based interventions into standard cardiovascular care.
